AbbVie (ABBV) and Genmab (GMAB) announce a late-stage trial setback for bispecific antibody, Epkinly in diffuse large B-cell ...
Deep Origin docking software and molecular dynamics simulations pinpointed the lead compound from a 17-compound libraryComputational results ...
Samsung Medical Center announced on July 23 that a research team led by Professor Kim Seokjin of the Department of Hematology ...
People with DLBCL or high-grade B-cell lymphoma may be hospitalized after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems. People with FL ...
In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...
Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester ...
The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...
A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, ...
Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results